21% Response Rate for Previously Treated Melanoma Using Nivolumab and Ipilimumab

21% Response Rate for Previously Treated Melanoma Using Nivolumab and Ipilimumab

User Photo
AnnualMeeting-SITC2017

4 years
256 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Claire Friedman, MD of Memorial-Sloan Kettering discusses the use of combination therapy for patients with melanoma at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Up Next Autoplay